February Anatara News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Anatara Lifesciences Ltd (ASX:ANR) Q3 FY21 Activities Report
  
Q3 FY21 Activities ReportMelbourne, April 27, 2021 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Company s Appendix 4C cash flow report.
Commenting on the quarter, CEO Steve Lydeamore said, Anatara is pleased to have successfully progressed two key milestones during the period - a successful trial for Anatara s proprietary enriched formulation for poultry in water, and ethics approval to start the human IBS trial.
Anatara now has approval to commence two separate human trials for its Gastrointestinal Re-Programming complementary medicine (GaRP), and there appears to be a wider appreciation of the Company s human health initiatives and the potential to improve overall human wellbeing with ....

April Anatara , Anatara Ga , Steve Lydeamore , Anatara Lifesciences , Human Research Ethics Committee , Anatara Lifesciences Ltd , Company Appendix , Gastrointestinal Re Programming , February Anatara , Psychological Functioning Trial , Escherichia Coli , Drugs Otc , Health Pharm General , Asx Anr , மனிதன் ஆராய்ச்சி நெறிமுறைகள் குழு , நிறுவனம் பின் இணைப்பு , இரைப்பை குடல் ரே ப்ரோக்ராமிஂக் , மருந்துகள் ஆரீட , ஆரோக்கியம் பார்ம் ஜநரல் , அஸ்ஸ் ஆர் ,